JPMorgan Reduces PT on Syndax Pharmaceuticals (SNDX) to $33, Maintains “Overweight” Rating

Core Insights - Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) is recognized for its significant upside potential and is listed among the best small-cap biotech stocks to buy according to analysts [1] Financial Performance - For Q3 2025, Syndax reported a 21% increase in total revenue, reaching $45.9 million, driven by strong uptake of its lead therapies [3] - The company’s net loss narrowed to $60.7 million, or $0.70 per share, compared to a loss of $84.1 million, or $0.98 per share, in Q3 2024 [4] - Syndax ended the quarter with cash balances of $456 million, which is sufficient to support ongoing operations and pipeline development until profitability [4] Product Developments - Revuforj was included in NCCN guidelines and received FDA approval for a broader patient population, significantly contributing to the company's growth [3] - Niktimvo recorded annualized revenue of $200 million, indicating strong market performance [3] Analyst Ratings - JPMorgan reduced its price target for Syndax from $40 to $33 while maintaining an "Overweight" rating, reflecting adjustments in their models for the SMID-cap biotechnology group [2]